Search

Your search keyword '"Rodriguez, María J."' showing total 41 results
Start Over Author "Rodriguez, María J." Search Limiters Peer Reviewed
41 results on '"Rodriguez, María J."'

33. Survival after heart transplantation for Chagas cardiomyopathy using a conventional protocol: A 10‐year experience in a single center.

Author

Echeverría, Luis E., Figueredo, Antonio, Rodriguez, María J., Salazar, Leonardo, Pizarro, Camilo, Morillo, Carlos A., Rojas, Lyda Z., Gómez‐Ochoa, Sergio A., and Castillo, Victor R.

Subjects
HEART transplantation, LIFESAVING, CAUSES of death, CARDIOMYOPATHIES, HEART failure patients, PROGNOSIS
Abstract

Background: Heart transplant (HT) remains the most frequently indicated therapy for patients with end‐stage heart failure that improves prognosis in Chagas cardiomyopathy (CCM). However, the lack of benznidazole therapy and availability of RT‐PCR follow‐up in many centers is a major limitation to perform this life‐saving intervention, as there are concerns related with the risk of reactivation. We aimed to describe the outcomes of a cohort of patients with CCM who underwent HT using a conventional protocol with mycophenolate mofetil, without benznidazole prophylaxis or RT‐PCR follow‐up. Methods: Retrospective cohort study. Between 2008 and 2018, 43 patients with CCM underwent HT. A descriptive analysis to characterize outcomes as rejection, infectious and neoplastic complications and a survival analysis was carried out. Results: Median of follow‐up was 4.3 (IR 4.28) years. Survival at 1 month, 1 year, and 5 years was 95%, 85%, and 75%, respectively, infections being the main cause of death (60%). Reactivations occurred in only three patients (7.34%) and were not related to mortality. Conclusion: This cohort showed a favorable survival and a low reactivation rate without an impact on mortality. Our results suggest that performing HT in patients with CCM following conventional guidelines and recommendations for other etiologies is a safe approach. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

36. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.

Author

Riggio, Marina, Perrone, María C., Polo, María L., Rodriguez, María J., May, María, Abba, Martín, Lanari, Claudia, and Novaro, Virginia

Abstract

The purpose of this study was to elucidate the mechanisms associated with the specific effects of AKT1 and AKT2 isoforms in breast cancer progression. We modulated the abundance of specific AKT isoforms in IBH-6 and T47D human breast cancer cell lines and showed that AKT1 promoted cell proliferation, through S6 and cyclin D1 upregulation, but it inhibited cell migration and invasion through β1-integrin and focal adhesion kinase (FAK) downregulation. In contrast, AKT2 promoted cell migration and invasion through F-actin and vimentin induction. Thus, while overexpression of AKT1 promoted local tumor growth, downregulation of AKT1 or overexpression of AKT2 promoted peritumoral invasion and lung metastasis. Furthermore, we evaluated The Cancer Genome Atlas (TCGA) dataset for invasive breast carcinomas and found that increased AKT2 but not AKT1 mRNA levels correlated with a worse clinical outcome. We conclude that AKT isoforms play specific roles in different steps of breast cancer progression, with AKT1 involved in the local tumor growth and AKT2 involved in the distant tumor dissemination, having AKT2 a poorer prognostic value and consequently being a worthwhile target for therapy. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results